Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).
Bartomeu Massuti
No relevant relationships to disclose
Rosario García Campelo
No relevant relationships to disclose
Delvys Rodriguez Abreu
No relevant relationships to disclose
Jordi Remon
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Elisa Galvez
No relevant relationships to disclose
Jose Antonio Ortega
No relevant relationships to disclose
Francisco Aparisi
No relevant relationships to disclose
Noemi Reguart
No relevant relationships to disclose
María Ángeles Sala
No relevant relationships to disclose
Dolores Isla
No relevant relationships to disclose
Maria Sanchez Ronco
No relevant relationships to disclose
Ana Verdu
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Clara Mayo-de las Casas
No relevant relationships to disclose
Eva Pereira
No relevant relationships to disclose
Rosana Cajal
Employment or Leadership Position - AstraZeneca Spain
Maria Carmen Gonzalez-Arenas
Employment or Leadership Position - AstraZeneca Spain
Enric Carcereny
No relevant relationships to disclose
Rafael Rosell
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca